Spinal muscular atrophy
Further expanding the clinician’s armamentarium
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
“Take her home, love her, and we will strive together to prioritize her quality of life as her symptoms progress”: this is what many parents recall hearing when receiving a diagnosis of spinal muscular atrophy (SMA) in the past. The most common inherited basis of infant death, SMA is caused by recessive, loss-of-function mutations of SMN1 (survival motor neuron 1 gene), with retention but altered splicing of SMN2, deficient expression of SMN protein, and degeneration of motor neurons causing profound muscle weakness. Two-thirds of patients with SMA develop symptoms before age 6 months, and without interventions of tube feeding and mechanical ventilation, had a nearly 100% mortality rate at age 2 years.1
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
See page 640
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis
Dr. Robert Pitceathly and Dr. William Macken
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Impaired kidney structure and function in spinal muscular atrophyFlávia C. Nery, Jennifer J. Siranosian, Ivy Rosales et al.Neurology: Genetics, August 12, 2019 -
Research
Nusinersen Treatment in Adults With Spinal Muscular AtrophyTina Duong, Connie Wolford, Michael P. McDermott et al.Neurology: Clinical Practice, January 25, 2021 -
Special Article
Evidence in focus: Nusinersen use in spinal muscular atrophyReport of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of NeurologyDavid Michelson, Emma Ciafaloni, Stephen Ashwal et al.Neurology, October 12, 2018 -
Articles
SMN mRNA and protein levels in peripheral bloodBiomarkers for SMA clinical trialsC. J. Sumner, S. J. Kolb, G. G. Harmison et al.Neurology, February 15, 2006